Tuomas R. Holmberg

Fondatore presso NovaDigm Therapeutics, Inc.

Consumer Services

Health Technology

Profilo

Tuomas R.
Holmberg is the founder of NovaDigm Therapeutics, Inc. where he currently holds the title of Director & Chief Business Officer.
Mr. Holmberg is also the founder of Collector Crypt.
Mr. Holmberg's education history includes an MBA from the University of Southern California and an undergraduate degree from the California Institute of Technology.

Posizioni attive di Tuomas R. Holmberg

Società	Posizione	Inizio
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Fondatore	01/01/2005

Tutte le posizioni attive di Tuomas R. Holmberg

Precedenti posizioni note di Tuomas R. Holmberg

Società	Posizione	Fine

Vedi nel dettaglio l'esperienza di Tuomas R. Holmberg

Formazione di Tuomas R. Holmberg

University of Southern California	Masters Business Admin
California Institute of Technology	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Tuomas R. Holmberg

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Health Technology